News | March 13, 2025
Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Havix was incorporated under the laws of the State of Delaware on February 17, 2015
The European regulator will conduct a re-inspection of the facility to verify the compliance
This MoU marks a significant milestone in interdisciplinary research, paving the way for scientific advancements in homoeopathy
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
This addition strengthens Dr. Agarwals Eye Hospital's vast network of 28 hospitals across Karnataka and 220+ facilities worldwide
Biotech potential of Himalayan territories including Jammu & Kashmir, particularly their agri-biotech potential remains still under-explored
USFDA inspection at Alembic Pharma's Bioequivalence facility
Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto® Tablets, 2.5 mg of Janssen Pharmaceuticals
This termination of Agreement will not have any significant impact on the company and/or its subsidiaries or its financials
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
